ASTC · Astrotech Corporation

Astrotech's Q3 FY2026 results reflect a strategic shift from development to commercialization, evidenced by a 28% reduction in R&D expense to $554 thousand as the company advances EN-SCAN Handheld GC and TRACER 1000 products toward sales. Revenue dropped 36% year-over-year to $343 thousand, with gross profit margins contracting sharply to 20% from 44%, driven by a 7% lower cost of revenue at $276 thousand. Operating expenses decreased modestly to $3.5 million, primarily from R&D efficiencies, narrowing the operating loss to $3.5 million from $3.9 million. CEO Thomas B. Pickens emphasized disciplined execution, cost controls, and a robust sales pipeline supported by 37 TRACER 1000 deployments across 16 countries, demonstrating real-world validation of mass spectrometry technology. Balance sheet liquidity contracted with cash falling to $2.7 million from $3.1 million at fiscal year-end, alongside short-term investments at $3.9 million, signaling tighter working capital amid ongoing investments in high-return areas. No forward guidance was provided, but management highlighted balancing expense discipline with pipeline conversion for future revenue growth.